Won’t get fooled again? GlaxoSmithKline and access to data

On November 22nd the European Medicines’ Agency (EMA) is holding a workshop on access to the data from clinical trials.

While there have been many efforts by many people over the years to make the clinical trial process more transparent, the EMA workshop has come about primarily following the efforts of Peter Goetsche of the Danish Cochrane Group and Peter Doshi and Tom Jefferson from another Cochrane group.

Peter Goetsche

In 2007, Goetsche began the ball rolling by asking EMA to provide access to study reports on the weight loss drugs rimonabant and sibutramine – both since withdrawn because of suicide risks among other issues. EMA refused citing commercial confidentiality. Goetsche argued EMA were in breach of EU treaties. He appealed to Nikiforous Diamandouros, the European Ombudsman, and also applied to the Danish Medicine’s Agency for comparable data. In August 2009, he got some of the data from the Danish Agency. Diamandouros then required the EMA to provide access to all the data, and in February 2011 the data finally came. Goetsche wrote up the saga and has made the entire correspondence available online.

Peter Doshi & Tom Jefferson

The other driving force came from Peter Doshi and Tom Jefferson’s efforts to conduct a Cochrane review on Roche’s antiviral for influenza – Tamiflu. With recent scares about Avian and later Swine Flu, and other potential pandemics, governments around the world stockpiled billions of dollars worth of this under the impression it saved lives by reducing transmission, kept people out of hospital and got them back to work faster. The first publications from Doshi and Jefferson’s efforts to review the evidence began to appear in 2009 in the BMJ. Doshi and Jefferson asked Roche for access to the data – they agreed – but never delivered.  They have since told the story in many places (Op-Ed New York Times), outlining the billions of dollars lack of access has cost us. The BMJ have picked the issue up as the most clear cut case on which to campaign for data access. Roche’s resistance have been a gift that keeps giving for those in favor of data access.

Andrew Witty?

Meanwhile GlaxoSmithKline have been winning kudos after their CEO Andrew Witty promised to make the data from their clinical trials available. This offer has been welcomed glowingly by the BMJ, who civilly steered clear of mentioning the fraud action for withholding trial data that led to a $3 Billion fine for GSK.

Over a decade ago before merging with SmithKline, Glaxo-Wellcome made a comparable offer of transparency. Perhaps good Glaxo has got the upperhand on the more worldly SmithKline – lawyers sometimes put GSK’s aberrations down to legacy issues. But there are wrinkles – this is not unfettered access. A panel set up by the company will vet applications to access the data. The BMJ slid over this.

Maybe good Glaxo has got the upper hand but perhaps the BMJ should have resisted the temptation to gush. Even if they were just being civil, the gush factor will lead many who don’t understand the way the “English” read between lines to think that industry have undergone a Damascene conversion. GSK’s “gift” is a far more effective form of resistance than Roche’s.

Robert Gibbons??

The best way to explain what GSK may be up to is perhaps to repeat the wonderful story of Robert Gibbons – modest hero.

On May 1 this year, The Scientist ran an article, Data Diving, on the benefits of data access. It said what every article on this subject says – in the presence of full and unfettered access to scientific data the truth will out, while without access, companies can claim their trials show whatever the company wants them to show, get to charge whatever they want for their products and can hide what they know about any harms.

Data Diving opens with the struggles of Doshi, Jefferson and colleagues to get access to the data on Roche’s Tamiflu.  It then portrays Robert Gibbons as a member of the same club as Goetsche, Doshi and Jefferson, a pioneer in favor of unfettered access to data, who with access to patient level data denied to others has been able to turn myths on their head.

The truth is infinitely more intriguing. Gibbons, a professor at the University of Illinois and regular expert witness for pharmaceutical companies, published two articles  in Archives of General Psychiatry in early 2012 claiming that patient level data from trials of Lilly’s Prozac and Wyeth’s Effexor (see Coincidence a fine thing & May Fool’s Day) showed that in contrast to media hype antidepressants in fact work very well and don’t cause suicide. It was, it turns out, lack of access to the data that led us to these mistaken beliefs. Companies don’t engage in conspiracies, they are masters of the cock-up, and if given a choice of feet to shoot themselves in will opt for both feet. It needs independent academics like Robert Gibbons to wade in and put a stop to their self-injurious behavior, and show the world how good these drugs truly are.

Fooling the Journals

The writers of The Scientist, the Lancet and BMJ were fooled by superficial similarities into classifying the Fool’s Gold of Gibbons with the real gold of Goetsche, Doshi and Jefferson. They managed this despite the fact that very few articles in recent years in the psychiatric or any other literature have received such withering critique as Gibbons’ articles – see boringoldman, and madinamerica by Bob Whitaker. Medscape, National Public Radio, the Los Angeles Times and other outlets from Canada to Australia gave Gibbons airtime and print space in what at one point looked to me like a campaign to roll back the Black Box warnings of suicidality on antidepressants.

Gibbons in fact didn’t have access to anything the original authors of the Prozac papers hadn’t already had access to.  The original authors were all Lilly personnel with presumably even fuller access than Gibbons was later given. Gibbons also managed to steer clear of other data in the public domain that could be readily accessed that show incontrovertibly that Prozac and Effexor can not only trigger suicide but that the clinical trial data shows that on balance there are more lives lost on these drugs than saved.

Perverting Science

By ignoring relevant accessible data in favor of data no-one else can access, Gibbons has turned the standard access to data argument on its head and made access to data that comes through companies a potential liability for all of us. It’s hard to call the Gibbons version of data access anything less than a perversion.

Last May (May Fool’s Day) I joked that the only explanation for The Scientist getting things so badly wrong seemed to be that they were trying to perpetrate a hoax. The best response of course was to carry on in joke mode and in this vein I suggested Dr. Gibbons should be invited to chair an interview panel to recruit academics to whom companies would be prepared to make data available in the manner Lilly and Wyeth had done.

The joke has turned extremely black. This is almost exactly the mechanism Andrew Witty has just proposed for GSK’s data – to warm applause from the BMJ.

Perverting Journals

What happened next in the Gibbons story is a cautionary tale. Several sets of academics – Glen Spielman and colleagues, Barney Carroll, Mickey Nardo, and Matthew Miller and colleagues all wrote to Archives pointing out the lethal flaws in the Gibbons papers that ranged from inappropriate data inclusion to incompetent mathematical calculations to biased interpretations. Letters like this would once have been published in a good journal – science depends on robust debate about the data shows. Without debate of this kind error is propagated and the self-correcting function of science is disabled.

But Archives refused to print. They offered to consign the letters to an online limbo where they would be untraceable for anyone interested to chase the issues.

Why publish when on the face of it, Gibbons was claiming access to data that his critics didn’t have? Science does not depend on publishing the rants of people who are unhappy about something but have not analyzed the data. From an editor’s point of view allowing letters that were not based on the data seems to be tackling the man rather than the issue.

But in a bizarre twist six months later Glen Spielmans got a voice mail from someone named Debbie at the behest of the Archives editor (J Coyle) stating “Dr. Coyle has sent you an accept letter for your letter regarding the Gibbons papers…”. Why?

The Plot to Capture Data Access?

So what’s going on? Are GSK making an offer aimed at frustrating the EMA process? Offering to give access to their data through an academic body is the kind of move that would appeal to politicians and might lead them to step back from granting the kind of unfettered access to the data that EMA have been offering in recent months. For politicians, what’s not to like about the GSK offer? It would come wrapped in company commitments to ensure good research governance, panels of experts, and boxes to tick. And joy of joys it would produce a succession of Robert Gibbons rather than the Tom Jeffersons, who embarrass governments as well as companies.

 The Long March

Before asking the tantalizing question as to why Archives suddenly backed down, there’s a twist to the Gibbons’ Legacy to explore.

In June 2009, Gibbons had chaired an Institute of Medicine public workshop that brought together experts from industry, academia, government, and advocacy groups to discuss the issue of managing perceptions of suicidality on psychotropic drugs. The participants were asked to examine and discuss currently available data, data analysis, and the future of potential partnerships in the area of clinical trials involving the nervous system.

The Planning committee included

WILLIAM POTTER (Co-chair), Merck Research Laboratories, an NIMH based defender of Prozac in 1991 who soon after joined Lilly
ROBERT GIBBONS (Co-chair), University of Illinois at Chicago
CHARLES BEASLEY, JR., Eli Lilly and Company
DAVID BRENT, University of Pittsburgh School of Medicine – an outspoken critic of the Black Box.
YEATES CONWELL, U of Rochester School of Medicine – colleague of Eric Caine below, networked to Tom Laughren
WALTER KOROSHETZ, Nat Inst of Neurological Disorders & Stroke
THOMAS LAUGHREN, Food and Drug Administration – the FDA official who likely has hidden evidence of harm over a longer period than any other
HUSSEINI MANJI, Johnson & Johnson Pharmaceutical
DAVID MICHELSON, Merck & Co.
ATUL PANDE, GlaxoSmithKline, Inc.
PHILIP WANG, National Institutes of Health – expert witness for GSK and voter against the Black Box Warning

This was billed as a consensus conference. Consensus conferences are supposed to bring proponents of differing viewpoints together in an attempt to find common ground but it would be close to impossible to have found differences between these participants before the meeting began. Calling this a consensus conference is a wonderful irony.

The project was supported by the National Academy of Sciences, the National Science Foundation, the Alzheimer’s Association, Astra-Zeneca, CeNeRx Biopharma, the Department of Health and Human Services, National Institutes of Health (including the Nat Inst on Aging, Nat Inst on Alcohol Abuse and Alcoholism, Nat Inst on Drug Abuse, Nat Eye Inst, the NIH Blueprint for Neuroscience Research, NIMH, Nat Inst of Neurological Disorders & Stroke), Eli Lilly, GE Healthcare, GSK, Johnson & Johnson, Merck Research Laboratories, the Society for Neuroscience and Wyeth. So it was clearly very important to a lot of people.

At it Gibbons recommended examining the item-3 of the weekly Hamilton Depression Rating Scale, the suicide item, and the degree of suicidal ideation and planning according to four levels of severity— plus overall Hamilton weekly ratings to determine treatment responsiveness and suicide attempts. He and Charles Beasley of Eli Lilly, he said, were conducting a reanalysis of the RCT data to determine whether this approach improves suicidal ideation as a predictor of suicidality. This he suggested was better than the approach taken by FDA in 2004-2006.

This was the exact same approach taken by Beasley and Lilly in 1991. It had been rejected by FDA in 2004 and 2006. It was this “new” research that gave rise to the papers he published in 2012 – without Beasley’s name on them.

A report came out of the meeting. “This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise in accordance with procedures approved by the NRC’s report review committee.  The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence and responsiveness to the study charge.”

The reviewers included Charles Beasley, Eric Caine (See Y Conwell above), J Greenhouse and R Temple (T Laughren’s boss at FDA). This was a very closed circle.  What were they up to?

the 2009 watershed

There was another “consensus conference” in March 2009 that featured many of the same participants, notably Charles Beasley, along with Herb Meltzer and other academics in collaboration with FDA and industry on the topic of suicidality. This was written up in the Journal of Clinical Psychiatry.

These groups appeared to be all desperately grappling with a need to find some way to stop people – patients or doctors – believing the evidence of their own eyes. When someone becomes suicidal on an antidepressant and it clears up when the drug is stopped and reappears when the drug is started again, this is conclusive evidence the drug causes suicide. But over the last 20 years companies have deployed rating scale data, arcane classification systems for suicidal events, miscoding of events,, statistical significance and lack of access to the clinical trial data as ways to obscure the problem.

There was a lot more happening in 2009. To me all this activity looked like a concerted effort to roll back the Black Box. The only reason to think not, was that it didn’t make any sense that people would want to roll back the Black Box – which had had almost no effect on clinical practice or the sales of drugs. But whatever this effort might have started out as, the real fruit of the exercise may well have been the Gibbons experiment. It’s hard to see any reason for rolling out a set of publications than repeated a 20 year old discredited article other than as an experiment to see what might happen if companies stood the data access argument on its head.

Why did Archives suddenly back down? Having tested the model and found it works beautifully, putting GSK in a wonderful position to make their offer, secure in the knowledge that this was a close to perfect way to control the scientific process – why draw attention to what’s going on?

Why would Archives play ball? For journals, there is the tempting prospect on the one hand of a series of apparently data-driven Gibbons-type papers that have all been through a strict research governance process that will win the journal huge amounts of money in reprint fees, rather than on the other hand a series of articles a la Doshi, Goetsche and Jefferson, that will get them nothing in reprint fees, will risk tying them up in legal knots and might even put them out of business.

Too paranoid? Not paranoid enough.

Too English? Far too English.

[Conflict of Interest:  I have  a serious conflict of interest with this piece that will be laid out in the next post].


RxISK: Research and report prescription drug side effects on RxISK.org.

Search. Report. Contribute.


You and your meds. Give the real story. Get the real story.

Pharmageddon

Pharmaceutical companies have hijacked healthcare in America, and the results are life-threatening.

 

Dr. David Healy documents a riveting and terrifying story that affects us all.

 

University of California Press (2012)

 

Available on Amazon.com

 

Comments

  1. Yes I believe you’re right there appears to be an effort to discount the FDA’s Black Box Warning for suicide on SSRIs. The AACAP is also doing it. The fact of the matter is here in the US there is an effort to not do the right or ethical thing for kids in general and in particular for kids who are State wards. It is as if the kids are a commodity, a source of revenue, and a pool of drug trial participants, etc.

  2. Bruce Charlton says:

    Nothing that Cochrane groups may in future do in relation to calls for access to trial data, can undo the vast harm they have already doneover (in alliance with ‘evidence-based medicine’) to propagandize and hammer-home so many ignorant and false ideas about the nature of randomized trials.

    In particular the Chchranes outrageous idea that large randomized mega-trails are intrinsically the best form of evidence concering drug effectiveness – which in practice has led to the nonsense that randomized trials are the only authoritative form of evidence concerning drug effectiveness.

  3. If you are startlingly intelligent like you are, and like I am, then there is not a chance that Sir Andrew Witty will last the course.

    I said before, I like analogies, and Sir Andy is way beyond what Sir Savile did with his own particular form of abuse. Sir Jim has now over 450 cases of abuse directed at him. He is now publicly pilloried and deried as one of the worst abusers of children this country has ever entertained.

    Sir Andy has thousands of cases of abuse from Seroxat/Paxil directed at him regarding children and adults. So what about a trial and get all the thousands who murdered themselves, their friends, their relatives, total strangers, and put Andy in the courtroom, where he has not yet appeared, in the UK.

    And let him answer the billion dollar question ‘does Seroxat cause suicide, self-harm, anger, aggression, and destruction of the will to live?’

    He will look pained, he will say, ‘Glaxo have overcome a $3 billion fine in the US, but it will not happen in the UK. We are transparent, we are cool, we are the good guys and even the drug regulators think we are the good guys.

  4. You can bet that GSK won’t grant access for patient advocates, bloggers, or lawyers! This nonsense about GSK transparency is simply untrue- the transparency is policed by GSK- therefore it’s hardly a humanitarian act on their part…

    Seems like a load of hot air to me! Makes for good PR sound bites- but in reality a bit of a damp squib …

    Rather like Glaxo’s offer of access to the MHRA in regards to the Seroxat criminal investigation some years ago. (which of course ended in no charges against GSK)

    Jean-Pierre Garnier (the former CEO of GSK) was asked my James Naughtie on BBC radio “:

    “Does this mean that all the information GSK holds on the development of Seroxat will be put in the public domain?”

    . This comprised “millions of documents, millions”, Garnier countered, “this has to be orchestrated, organized and the requests have to be specific”.

    How can the regulators, scientists or whomever needs the information, know what to ask for?

    http://seroxatsecrets.wordpress.com/2008/05/20/jp-garnier-does-what-gsk-other-employees-did-simply-refuses-to-answer-questions-about-seroxat/

  5. The transparency claim by Glaxo is nothing new. They did the same after the Spitzer settlement. Glaxo have been forced to open their doors, probably as part of their recent agreement with the Department of Justice in the States.

    Here we have a company who, at every given opportunity, like to cover themselves in garlands – they even attempt it when they are wrong – see recent excuses for their record fine.

    I’m convinced a deal was struck with the DOJ. The trial was kept under wraps for 10 years – so, we had 10 years of poor drugs being given to patients, all the time the DOJ kept quiet.

    Even more bizarre is the fact that this case had been kept sealed for 10 years during which time Eric Holder, Attorney General of the United States, became involved. Here’s where things start to get confusing and one could shout ‘conspiracy’ if they so wished but if you follow the trail you start to make sense of things a little better.

    You see Holder’s involvement in this case, some would say, stinks of something acrid, particularly when you join the dots and learn that he was once a defence attorney for Covington Burling… the very same law firm that represented Glaxo in the recent whistleblower action.

    You confused?

    What role did the US Attorney General Eric Holder play in all of this? It’s a fair enough question, given his background. No accusations here, just questions. I’ll leave US politics to those who understand the mechanics of it all.

    I wrote about this back in October, here – http://fiddaman.blogspot.co.nz/2012/10/glaxos-murky-transparency-claim.html

  6. Meant to say ..

    Excellent blog post Dr Healy,

    It is quite remarkable how the BMJ, and other media outlets, fail to see the ironies of this dafa-access situation. As you have very clearly pointed out- this is quite the coup for GSK… and whilst it provides the illusion of access (it will remain strictly under the control of GSK in regards to who gets too see the data). It also potentially shuts down the other avenues which were finally beginning to open up for independent academics – such as Goetsche’s successful appeal through the European Ombudsman..

    The devil’s in the details…
    Great insight and analysis into this data-debate Dr. Healy

    I hope that your blog is being widely read!
    It’s excellent.

    :)

  7. Since 1997, EMA is talking about transparency.
    In november 2010, I have asked EMA for some raw data about a product approved on one clinical trial which I think was biased. (I had already sent a short paper to EMA about my doubts on this trial in 2009)
    I did not get the data and lodged a complaint with the European ombudsman in April 2011. (0693/2011/(ELB)RA)
    Unfortunately, EMA “could not retrieve the document from the archives”
    I finally decided to published my doubts : http://www.la-press.com/redirect_file.php?fileId=4504&filename=Approved-Beta-Interferons-in-Relapsing-Remitting-Multiple-Sclerosis_Odd_One_Out2&fileType=pdf

    4 of the speakers of tomorrow EMA workshop are aware of this case of unsuccessful data request.
    Let us hope that in a few hours workshop, they will fix a 15-year long problem

  8. Another example of what you often write about:

    “Roche Pharmaceuticals, manufacturer of Tamiflu (oseltamivir phosphate) – marketed as ‘a prescription drug…an oral antiviral treatment (not a vaccine!) for influenza, belong(ing) to a class of medicines called neuraminidase inhibitors (NAI) ostensibly designed to be active against all clinically relevant influenza virus strains…proven to be effective in the treatment and for the prevention of influenza in adults and in children 1 year and older’, are currently facing intense scrutiny in Medical circles, for deliberately withholding primary Clinical Trial data on Tamiflu. Under pressure from a UK Government led commission investigating the safety & efficacy of neuraminidase inhibitors, the British Medical Journal (BMJ), backed by the Cochrane Collaboration (a non-profit international organization comprised of the world’s leading Medical researchers & practitioners) have jointly accused Roche of deliberately withholding the majority of “full study reports” pertaining to the anti-viral drug Tamiflu, including suppressing potentially damning evidence of adverse side effects.

    “8 of the 10 RCT’s (randomized controlled trials), on which effectivcness claims (of Tamiflu) were based, were never published, and the only 2 that had been published were funded by Roche and authored by Roche employees and Roche-paid external experts…The Cochrane reviewers now know that there are at least 123 trials of Tamilfu and that the majority (60%) of patient data from Roche Phase 3 completed treatment trials remains unpublished. There are concerns on a number of fronts: the likely overstating of effectiveness and the apparent under-reporting of potentially serious adverse effects.”

    http://vaccineresistancemovement.org/?page_id=11240

  9. Robert Gibbons has been well rewarded, at least. After thirty years at UIC, he is movin’ on up … In November of 2010, he and his entire “Center for Health Statistics” moved to the University of Chicago, Pritzker School of Medicine. In March 2011 Greenhouse and Sharon-Lise Normand joined the Center. And a month later Gibbons was named a Pritzker Scholar for 2011. What’s that, you ask?

    “The Pritzker family of Chicago, widely known philanthropists whose many business ventures include the Hyatt Hotel chain, made a gift of $30 million to the University of Chicago in 2002. The gift has been used to recruit outstanding new faculty to the Biological Sciences Division of The Pritzker School of Medicine. These Pritzker scholars form uniquely synergistic and powerful groups of investigators. To date, there have been 18 Pritzker Scholars.”

    You won’t be too surprised to learn that a lot of the Pritzker family capital is tied up in pharma and biotech these days. Or that family spokesperson Penny Pritzker was and is Obama’s top fundraiser. The relationship between Pharma and both parties remains pretty “synergistic and powerful.”

    Lately Gibbons has coauthored several articles casting doubt on the link between leukotriene-modifying asthma medications (like Singulair) and suicide:

    http://www.ncbi.nlm.nih.gov/pubmed/21663330
    http://www.ncbi.nlm.nih.gov/pubmed/22698520
    http://www.ncbi.nlm.nih.gov/pubmed/2204610

    The first one includes a bit of finagling crude enough for even me to catch: It examines reports “between 1995 and 2010” although 96% of these reports came in the past two years! (It also claims both asthma and allergic rhinitis are themselves “associated with suicide” which is news to me.) The last one speculates that these meds may even lower suicide rates. Keep a close watch on your children, folks, and when they sneeze … Ask Your Doctor.

  10. Colour me cynical but even if the doors are thrown open to inspection of the raw data, there is no guarantee that what will be revealed actually shows the real problem. Having been a whistleblower I know this intimately. The situation was that the raw data, on paper could have been viewed by anyone and nothing untoward seen. The real problem was that the study involved extensive psychological testing that had been performed while the building was undergoing construction with hammering, circular saws, nail guns going off constantly. This, of course, invalidated all of the data obtained under such conditions. So, even if it seems to be transparent, I’d be more than reluctant to accept any of it. Even NIH studies conducted with objective oversight teams can’t guarantee that the “oversight” will be constant. If it were, I’d be more inclined to accept that what you see is was what was obtained.

  11. OOPS — last link to article crediting Singulair for reducing suicide was wrong. Here’s the right link:

    http://www.ncbi.nlm.nih.gov/pubmed/22046105

Leave a Comment

*